These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14503994)

  • 1. Products of advanced glycation in patients with type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Pokupec R; Turk N; Stavljenić-Rukavina A
    Ann Clin Biochem; 2003 Sep; 40(Pt 5):552-9. PubMed ID: 14503994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
    Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy.
    Misur I; Zarković K; Barada A; Batelja L; Milicević Z; Turk Z
    Acta Diabetol; 2004 Dec; 41(4):158-66. PubMed ID: 15660198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel advanced glycation index and its association with diabetes and microangiopathy.
    Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
    Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy.
    Yamaguchi M; Nakamura N; Nakano K; Kitagawa Y; Shigeta H; Hasegawa G; Ienaga K; Nakamura K; Nakazawa Y; Fukui I; Obayashi H; Kondo M
    Diabet Med; 1998 Jun; 15(6):458-62. PubMed ID: 9632118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
    Stitt AW; Moore JE; Sharkey JA; Murphy G; Simpson DA; Bucala R; Vlassara H; Archer DB
    Invest Ophthalmol Vis Sci; 1998 Dec; 39(13):2517-23. PubMed ID: 9856760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C.
    Antoniades C; Tousoulis D; Tountas C; Tentolouris C; Toutouza M; Vasiliadou C; Tsioufis C; Toutouzas P; Stefanadis C
    Diabet Med; 2004 Jun; 21(6):552-8. PubMed ID: 15154938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of coronary artery disease and percutaneous intervention on the cardiac metabolism of nonesterified fatty acids and insulin: Implications of diabetes mellitus.
    Jaumdally RJ; Lip GY; Patel JV; MacFadyen RJ; Varma C
    J Intern Med; 2009 Jun; 265(6):689-97. PubMed ID: 19226374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
    Zhou H; Tan KC; Shiu SW; Wong Y
    Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure.
    Chello M; Spadaccio C; Lusini M; Covino E; Blarzino C; De Marco F; Di Domenico F; Coccia R
    Diabetes Metab Res Rev; 2009 Jul; 25(5):420-6. PubMed ID: 19405075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease.
    Kitamura M; Kitaichi N; Takeuchi M; Kitamei H; Namba K; Yamagishi SI; Iwabuchi K; Onoé K; Ohno S
    Br J Ophthalmol; 2005 Nov; 89(11):1407-9. PubMed ID: 16234440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
    Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma sRAGE is independently associated with high sensitivity C-reactive protein in type 2 diabetes without coronary artery disease.
    An XF; Zhao Y; Yu JY; Liu JS; Gu WJ; Gao F
    Diabetes Res Clin Pract; 2010 Mar; 87(3):e19-22. PubMed ID: 20031245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different role of advanced glycation end products in pathology of transplanted heart in patients with or without diabetes mellitus type 2.
    Zakliczynski M; Nozynski J; Konecka-Mrowka D; Pyka L; Trybunia D; Nikiel B; Mlynarczyk-Liszka J; Lange D; Zembala M
    Transplant Proc; 2009 Oct; 41(8):3185-9. PubMed ID: 19857706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caribbean female patients with type 2 diabetes mellitus have lower serum levels of adiponectin than nondiabetic subjects.
    Ezenwaka CE; Kalloo R
    Neth J Med; 2005 Feb; 63(2):64-9. PubMed ID: 15766010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects.
    Uribarri J; Stirban A; Sander D; Cai W; Negrean M; Buenting CE; Koschinsky T; Vlassara H
    Diabetes Care; 2007 Oct; 30(10):2579-82. PubMed ID: 17496238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
    Bansal S; Chawla D; Siddarth M; Banerjee BD; Madhu SV; Tripathi AK
    Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.